NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=125657&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) […]

NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125656&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Report with market evolution powered by AI – The globalbeta lactam and beta lactamase inhibitors marketsize is estimated to grow by USD 8.4 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 4.7% during the forecast period. Rising focus on novel drug developmentis driving market growth,with a trend

Report with market evolution powered by AI – The global ticket marketsize is estimated to grow by USD 554.2 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 29.7% during the forecast period. Success of movies due to increasing use of animationis driving market growth,with a trend towardshigh

(NYSE:NVO), SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) — Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now.

TheSchall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Symbotic Inc. (“Symbotic” or “the Company”) (NASDAQ:SYM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased the Company's

LOS ANGELES, CA / ACCESS Newswire / January 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE:NVO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder

Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc.(“Atara” or the “Company”)(NASDAQ: ATRA).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext. 7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Atara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Walgreens and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Pomerantz LLP is investigating claims on behalf of investors ofTransocean Ltd.(“Transocean” or the “Company”)(NYSE: RIG).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Transocean and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining